Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Nurx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD and Nurx Expand Access to ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Knight Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA\u00ae","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Rubric Capital Management","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","amount":"$225.7 million","upfrontCash":"$140.0 million","newsHeadline":"TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","amount":"$225.7 million","upfrontCash":"$140.0 million","newsHeadline":"TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by TherapeuticMD

    Menu

    TherapeuticMD

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              TherapeuticsMD

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

              Details:

              Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

              Lead Product(s): Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Imvexxy

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Mayne Pharma

              Deal Size: $225.7 million Upfront Cash: $140.0 million

              Deal Type: Licensing Agreement January 03, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TherapeuticsMD

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

              Details:

              Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

              Lead Product(s): Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Imvexxy

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Mayne Pharma

              Deal Size: $225.7 million Upfront Cash: $140.0 million

              Deal Type: Agreement December 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TherapeuticsMD

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

              Details:

              TherapeuticsMD has three growing assets whose value has been enhanced by the recent approval of both Annovera’s (segesterone acetate) supplemental NDA and lower-dose Bijuva, as well as the increasing relevance of convenient and safe contraceptive options for women.

              Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Rubric Capital Management

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Financing August 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TherapeuticsMD

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

              Details:

              The sNDA included minor revisions to Annovera (segesterone acetate) in vitro release testing specification that allowed for normal manufacturing variability, was approved by the FDA in August 2018 as the only long-lasting, reversible, procedure-free birth control.

              Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TherapeuticsMD

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TherapeuticsMD Announces Pricing of $110 Million Public Offering of Common Stock

              Details:

              TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products, IMVEXXY® (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity).

              Lead Product(s): Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Imvexxy

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cantor

              Deal Size: $110.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering February 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TherapeuticsMD

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock

              Details:

              TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products which includes IMVEXXY®, BIJUVA® and ANNOVERA®, and for working capital and general corporate purposes.

              Lead Product(s): Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Imvexxy

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Cantor Fitzgerald

              Deal Size: $30.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering November 10, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TherapeuticsMD

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Knight and TherapeuticsMD Announce Health Canada Approval of BIJUVA®

              Details:

              BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an intact uterus.

              Lead Product(s): Estradiol,Progesterone

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Bijuva

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Knight Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              TherapeuticsMD

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TherapeuticsMD and Nurx Expand Access to ANNOVERA®

              Details:

              The agreement is aimed at expanding access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require a medical procedure.

              Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Annovera

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Nurx

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY